Comparing Alkermes (NASDAQ:ALKS) & Actinium Pharmaceuticals (NYSE:ATNM)

Alkermes (NASDAQ:ALKS) and Actinium Pharmaceuticals (NYSE:ATNM) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.

Profitability

This table compares Alkermes and Actinium Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alkermes	3.96%	4.15%	2.19%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Insider & Institutional Ownership

95.2% of Alkermes shares are held by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 4.6% of Alkermes shares are held by insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations for Alkermes and Actinium Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1	4	12	1	2.72
Actinium Pharmaceuticals	0	0	1	0	3.00

Alkermes presently has a consensus price target of $54.56, suggesting a potential upside of 18.33%. Actinium Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 323.73%. Given Actinium Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Actinium Pharmaceuticals is more favorable than Alkermes.

Risk and Volatility

Alkermes has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of 0.05, indicating that its stock price is 95% less volatile than the S&P 500.

Valuation and Earnings

This table compares Alkermes and Actinium Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48 billion	5.24	$241.66 million	$0.38	121.34
Actinium Pharmaceuticals	$35.09 million	1.06	-$48.82 million	$0.36	3.28

Alkermes has higher revenue and earnings than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Summary

Alkermes beats Actinium Pharmaceuticals on 13 of the 15 factors compared between the two stocks.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company’s research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.